Citizens Rates Crinetics Pharmaceuticals (CRNX) buy
Citizens maintains a buy rating on Crinetics Pharmaceuticals with a price target of $95, a 183.50% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Citizens rated Crinetics Pharmaceuticals Inc ($CRNX) "buy" with a $95 price target on June 11, 2026.
Since the rating, $CRNX is up 7.0% after 1 week and up 5.5% to date (from the $33.53 close on Jun 11, 2026).
CRNX
Crinetics Pharmaceuticals Inc
Key Points
- On June 11, 2026, Citizens reiterated its buy rating on Crinetics Pharmaceuticals (CRNX), setting a price target of $95.
- Citizens's $95 price target implies 183.50% upside from Crinetics Pharmaceuticals Inc's ($CRNX) current $33.51 share price.
- The stock is currently trading at $33.51, significantly lower than its 52-week high of $85.01.
- Crinetics Pharmaceuticals is scheduled to report earnings on November 5, 2026, with analysts expecting updates on its clinical trials.
Get $CRNX trade alerts by text
We text you when insiders, Congress or big funds trade $CRNX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Crinetics Pharmaceuticals Inc alert may contain errors. Disclosures
Citizens Reaffirms Positive Outlook on CRNX
On June 11, 2026, Citizens reiterated its buy rating on Crinetics Pharmaceuticals Inc. (CRNX) with a price target of $95. The stock is currently trading at $33.51, reflecting a considerable gap from the target price. Crinetics focuses on developing treatments for rare endocrine diseases and related tumors, making this rating essential as the company navigates its clinical development phase.
Analysts Set New Price Targets
Recent analyst activity shows mixed feelings towards Crinetics. After Citizens’ announcement, firms including UBS and Evercore ISI Group downgraded their ratings to neutral or hold, with target prices around $85. This indicates a cautious approach from some analysts despite Citizens maintaining a bullish outlook.
Stock Performance Context
The stock currently trades well below its 52-week high of $85.01, suggesting potential undervaluation. With a market cap of approximately $9 billion, the company is navigating through significant clinical trials, which may influence its stock performance further. Investors will be keeping a close watch on the stock as it prepares for its next earnings report.
$CRNX price target
Crinetics Pharmaceuticals Inc daily closes and this analyst's $95 target. Not advice.
Upcoming Earnings
Crinetics is set to report its next earnings on November 5, 2026. Analysts are keen to see how the company’s lead product candidate, Paltusotine, progresses through its Phase 3 trials. The outcome could significantly impact the stock and the company’s future valuation.
What CRNX Does
Crinetics Pharmaceuticals, based in San Diego, California, is engaged in discovering and developing therapies for rare endocrine diseases. Its ability to advance its clinical programs could play a crucial role in its market performance, especially as it seeks to address unmet medical needs in this niche area of healthcare.
What’s Next for Crinetics
Looking ahead, investors will be watching the upcoming earnings report for signs of progress in Crinetics’ clinical trials and potential updates on its product pipeline. Citizens’ reaffirmed buy rating combined with the awareness of the recent downgrades from other analysts will be crucial in shaping market perceptions in the coming weeks.
Related Filing Alerts
Source: Citizens's rating change on $CRNX (Jun 11, 2026). Written by software, not financial advice. How we make alerts